Background: Chronic kidney disease (CKD) is associated with poor outcomes after percutaneous coronary intervention (PCI). This study aimed to evaluate the relationship between the degree of renal function at baseline and long-term clinical outcomes in coronary artery disease patients who underwent paclitaxel-eluting stent implantation. Methods: A total of 336 patients with 400 de-novo lesions underwent PCI between May 2007 and March 2009. The patients were divided into 4 groups: control (glomerular filtration rate (GFR) 90 ml/min; n = 132); mild CKD (GFR 60-89 ml/min; n = 112); moderate CKD (GFR <60 ml/min; n = 51); and dialysis (n = 41). All lesions were treated using a paclitaxel-eluting stent. The primary and secondary endpoints were incidences of mortality and major adverse cardiovascular events (MACE) during 2 years after PCI and target vessel revascularization (TVR), respectively. Results: Two-year MACE incidence rates were 9.7%, 15.2%, 30%, and 31% in control, mild CKD, moderate CKD, and dialysis groups, respectively. TVR trended upward with increasing renal impairment (8.3%, 12.5%, 18%, and 21.4% for the 4 groups, respectively, p = 0.09). Mild CKD, moderate CKD, and dialysis patients had adjusted hazard ratios of 2.51 (95% CI, 1.01-6.24); 3.20 (95% CI, 1.07-9.60); and 4.19 (95% CI, 1.30-13.51), respectively, for 2-year MACE. Conclusions: A graded relationship was observed between lower renal function and increased TVR, although it did not reach statistical significance. Cardiac death and TVR rates were significantly higher in moderate CKD and dialysis patients after paclitaxel-eluting stent implantation. Patients with reduced renal function, even mild CKD, were independent predictors of MACE.
Introduction
Chronic kidney disease (CKD) has been recognized as an important comorbidity factor in coronary artery disease (CAD) patients [1, 2] . Multiple data have demonstrated that 0914-5087/$ -see front matter © 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.jjcc.2010. 10.005 CKD is associated with increased risks of major adverse cardiovascular events (MACE) and mortality after percutaneous coronary intervention (PCI) [3] [4] [5] . Most studies defined CKD, as a fall in the serial estimated glomerular filtration rate (GFR) below 60 ml/min/1.73 m 2 [6] [7] [8] [9] [10] . However, renal function in CAD patients varies widely, ranging from subclinical renal insufficiency to dialysis. Therefore, patients with different levels of renal function may show different clinical outcomes after coronary intervention using the same stent. Drug-eluting stents (DESs) are widely used in clinical practice due to excellent outcomes with low rates of target vessel revascularization (TVR) at long-term follow-up [11] . Previous studies have reported that sirolimus-eluting stent implantation decreased the risk of repeat revascularization in CKD patients, but it did not decrease the mortality risk after PCI [7] [8] [9] . Still, the efficacy of paclitaxel-eluting stents has not been established for severe CKD and dialysis patients. Therefore, the aim of this study was to evaluate the relationship between degree of renal function at baseline and long-term clinical outcomes in CAD patients who underwent paclitaxel-eluting stent implantation.
Methods

Patient population and classification
This retrospective analysis comprised of only patients undergoing paclitaxel-eluting stent implantation (Taxus; Boston Scientific, Boston, MA, USA) at our hospital between May 2007 and March 2009. The following patients were excluded from the study: (1) patients with an in-stent restenosis lesion; and (2) patients who were treated with sirolimus-eluting or bare-metal stents. Finally, we found a total of 336 patients with 400 de-novo lesions who had successful paclitaxel-eluting stent implantation. Creatinine clearance was calculated using the Cockroft-Gault equation by considering parameters, such as age, sex, weight, and serum creatinine level, to estimate renal function [12] . Based on the Kidney Disease Outcomes Quality Initiative guidelines, CKD stages of the patients were further categorized as follows: stage1, normal or increased GFR ( 90 ml/min/1.73 m 2 ); stage 2, mild decreased GFR (60-89 ml/min/1.73 m 2 ); stage 3, moderately decreased GFR (30-59 ml/min/1.73 m 2 ); stage 4, severely decreased GFR (15-29 ml/min/1.73 m 2 ); stage 5, kidney failure (<15 ml/min/1.73 m 2 ) [13] . CKD stages 4 and 3 were considered as a single group because only 2 patients were categorized as CKD stage 4. All patients with CKD stage 5 were on hemodialysis. Finally, the patients were divided into the following 4 groups and analyzed: control (GFR 90 ml/min; n = 132); mild CKD (GFR 60-89 ml/min; n = 112); moderate CKD (GFR 59-20 ml/min; n = 51); and dialysis (n = 41).
Stent and post-procedural management
A bolus of heparin (100 IU/kg) was administered after sheath insertion and titrated to maintain an activated clotting time of >250 s throughout the procedure. Paclitaxel-eluting stent was positively used in our hospital during the period if not contraindicated; for example, for patients with planned surgical operations or with malignancies. Target lesions were predilated using conventional angioplasty balloons. After stent implantation, high-pressure balloon inflation was performed to achieve a satisfactory angiographic result of less than 25% residual stenosis by visual estimate. All patients received aspirin 100 mg plus clopidogrel 75 mg per day for at least 12 months and other cardiac medications as prescribed by the physicians.
Follow-up and definitions
The primary endpoints of the study were incidences of cardiac death and MACE (combined incidence of cardiac death, myocardial infarction, or TVR) during 2 years after PCI. The secondary endpoints were TVR and angiographic in-stent late luminal loss. All patients were scheduled to undergo follow-up angiography at 8 months after PCI. Clinical follow-up conducted for all patients included hospital visits and phone interviews at 30 days and 2 years after PCI. Quantitative coronary angiography was performed before, immediately, and 8 months after the procedure using edge detection algorithms. Minimal lumen diameter (MLD), reference vessel diameter, diameter stenosis, and lesion length were measured using a single matched worst view. Late lumen loss was defined as the difference between MLD immediately after the procedure and that at 8 months after PCI. Angiographic restenosis was defined as diameter stenosis >50% by quantitative coronary angiography at 8 months after PCI. TVR was defined as coronary artery bypass surgery involving the target vessel or PCI performed in the target lesion due to myocardial ischemia, combined incidence of death or myocardial infarction, or the incidence of stent thrombosis. Stent thrombosis was considered to have occurred when angiography confirmed the presence of either Thrombolysis in Myocardial Infarction (TIMI) flow grade 0 or 1, or flow-limiting thrombus occurring at any time after stent implantation [14] . The diagnosis of myocardial infarction required the presence of new Q-waves on electrocardiogram (ECG) and/or elevation of creatine kinase-MB isoenzyme (or total creatine kinase if creatine kinase-MB was not available) 2 times the upper limit of the normal range [15] . The patients who had cardiac complaints underwent a complete clinical, electrocardiographic, and laboratory evaluations. All patients provided written informed consent.
Statistical analysis
The data are presented as mean ± SD or counts (%). Differences between groups were assessed using the ANOVA test for continuous variables. Categorical data were compared using the Chi-square test. Event-free survival analyses were performed using the Kaplan-Meier method. Differences in cumulative adverse cardiac event rates and mortality were assessed using the log-rank test. The unadjusted and adjusted risks of MACE were assessed using hazard ratios (HRs) and 95% confidence intervals (CIs) derived from univariate and multivariate Cox regression models. To adjust for baseline differences, potentially relevant variables were entered into models if they showed univariable differences among the 4 groups with a p-value < 0.05. 
Results
The baseline clinical characteristics of the patients divided into the 4 groups according to baseline GFR are shown in Table 1 . Here 27% of the study population had moderately impaired renal function. As expected, several clinically relevant characteristics proved to be more severe in the low GFR groups. The patients in the low GFR groups were older than those in the control group, and often had diabetes, hypertension, prior myocardial infarction, and multiple coronary vessel disease. A higher proportion of women were seen in patients with moderate CKD. Moreover, the baseline hemoglobin level and left ventricular ejection fraction were significantly lower in moderate CKD and dialysis patients. At discharge, the patients with low GFR were less likely to receive statins and angiotensin-II receptor blocking agents. No differences were observed in terms of complex lesions and procedural data among the 4 groups (Table 2) . Notably, no significant differences were observed between control and mild CKD patients in terms of clinical and angiographic characteristics. The results of quantitative coronary angiography before and immediately after the procedures were not significantly different among the 4 groups (Table 3) . After 8 months, however, differences were observed in late lumen loss among the 4 groups (0.43, 0.60, 0.86, and 0.86 mm in control, mild CKD, moderate CKD, and dialysis patients, respectively). Notably, late lumen loss between moderate CKD and dialysis patients was identical. Differences in binary restenosis rates also remained significant among the 4 groups, especially between the groups with GFR <60 and 60 ml/min/1.73 mm 2 (30.4% vs. 12.8%, p = 0.002), whereas no difference was observed between control and mild CKD patients (11.8% vs. 14.1%, p = 0.76).
30-Day and 2-year clinical outcomes
The incidence of cardiac events at the first 30 days and 2 years after PCI is summarized in Table 4 . The 30-day MACE incidence rate was 1.8% (n = 6) and was not different among the 4 groups. Three cardiac deaths occurred in the moderate CKD group. Stent thrombosis during the first 30 days was observed in 1 patient from both the control and mild CKD groups. Two-year MACE incidence rates were 9.7% (n = 13), 15 .2% (n = 17), 30% (n = 15), and 31% (n = 13) in the control, mild CKD, moderate CKD, and dialysis groups (Fig. 1A) . No cardiac death was observed during 2 years in the control group, whereas 6 patients died (cardiac failure in 5 and sud- den death in 1) in the moderate CKD group, and 2 patients died (cardiac failure in both) in the dialysis group (Fig. 1B) .
A difference was observed in TVR at 2 years after PCI among the 4 groups. The revascularization rate by PCI revealed a tendency to increase as the CKD stage progressed (8.3%, 12.5%, 14%, and 19% in the control, mild CKD, moderate CKD, and dialysis groups, respectively, p = 0.27). Stent thrombosis occurred in 5 patients (1.5%) at 2 years after PCI. However, all cases of stent thrombosis were observed within 100 days after stent implantation (Fig. 2) . MACE and mortality rates were significantly higher in the patients with GFR <60 ml/min/1.73 mm 2 (12.3% and 0.4%, respectively) than in the patients with GFR 60 ml/min/1.73 mm 2 (30.4% and 8.7%, respectively) ( Fig. 1C and D) . In a Cox proportional hazards model, moderate CKD patients were at an increased risk of MACE (HR 4.10; 95% CI, 1.95-8.63; p = 0.0002) compared to control patients. Dialysis patients were also at a high risk of 2-year MACE (HR 3.88; 95% CI, 1.80-8.40; p = 0.0006) compared to control patients. After making adjustments for variables with univariable differences, including age, sex, over body weight, diabetes, insulin user, hypertension, anemia, and low left ventricular ejection fraction, baseline renal function remained a significant predictor of 2-year MACE (Fig. 3) . In comparison to control patients, mild CKD, moderate CKD, and dialysis patients had adjusted HRs of 2.51 (95% CI, 1.01-6.24), 3.20 (95% CI, 1.07-9.60), and 4.19 (95% CI, 1.30-13.51), respectively, for 2-year MACE.
Discussion
In this study, we evaluated the relationship between degree of renal function at baseline and long-term clinical outcomes in CAD patients who underwent paclitaxel-eluting stent implantation. The main findings of this study can be summarized as follows: (1) patients with reduced renal function, even mild CKD, were significant predictors of adverse cardiovascular events independently of baseline characteristics and treatments; (2) patients with GFR <60 ml/min/1.73 mm 2 had a significantly increased rate of occurrence of 2-year cardiac death; (3) angiographic restenosis rate and late lumen loss steadily increased with decreasing baseline renal function. As the results, a graded relationship was observed between lower renal function and increased TVR at 2 years after PCI.
Many studies have reported on higher mortality and cardiovascular events in CKD patients after successful PCI [7] [8] [9] . The precise reasons for high mortality and cardiovascular events are probably multifactorial. CKD patients are generally older and have higher prevalence of traditional coronary risk factors as shown in the present study. However, a post hoc analysis of the PRESTO trial demonstrated that an association between CKD and cardiovascular events was not significant after adjusting for coronary risk factors known to be associated with mortality [16] . These findings may indicate that the factor CKD also represents other nontraditional risk factors, such as the presence of anemia, inflammation, oxidative stress, calcium-phosphate disturbance, and coagulation abnormalities [17, 18] . The present study demonstrated that reduced renal function remained significant even after making adjustments for the differences in baseline characteristics and medical treatment among the 4 groups. Specifically, we demonstrated that even mild CKD was associated with an increased risk of cardiac death, myocardial infarction, or TVR as compared to control patients. In the era of BMS, Best et al. found that mild CKD patients have increased mortality rate at 1 year after successful PCI compared to patients with normal renal function [19] . Although a difference was not observed in cardiac mortality rates between the control and mild CKD patients in the present study, a significantly higher cardiac mortality rate was observed in moderate CKD and dialysis patients. The reason for cardiac death in patients with moderate CKD and dialysis was contributed by the high incidence of cardiac failure. A frequent peculiarity of pathological changes in moderate CKD and dialysis patients is plaque calcification and increased intima and media thickness [20] . In large conduit arteries, thickening and calcification of the media layer result in left ventricular afterload with the development of left ventricular hypertrophy [21] . These changes promote chronic myocardial ischemia due to an increased myocardial oxygen demand, and a deterioration of coronary perfusion and sub-endocardial blood flow distribution [22] . We found that an interventional strategy with DES is still ineffective in reducing cardiac mortality, and that the usage of statins, beta blockers, and angiotensin-II receptor blocking agents is still low for moderate CKD and dialysis patients. Therefore, it is conceivable that optimal medical intervention might be able to improve the poor outcomes in CKD patients [10] . Incidentally, there is a concern about the possible incidence of late stent thrombosis after DES implantation, but we did not find any associations between cardiac death and stent thrombosis during 2 years after PCI.
TVR and CKD in the DES era
Post hoc angiographic analysis of the TAXUS-IV trial showed that mean late lumen loss after paclitaxel-eluting stent implantation varied between 0.37 and 0.42 mm at all levels of renal impairment. Results from the above-mentioned Kaplan-Meier curve shows the survival free from definite stent thrombosis for the overall cohort. The incidence was 1.5% at 2 years. Figure 3 Multivariable adjustment for the association of CKD stage with the risk of cardiac death, myocardial infarction, or target vessel revascularization. Hazard ratio (HR) (squares) and 95% confidence interval (CI) (horizontal bars) are shown. CKD, chronic kidney disease; MACE, major adverse cardiovascular events. study showed that, TVR at 1 year was 6.9%, 8.0%, and 6.6% in the patients with normal renal function, mild CKD, and moderate CKD without dialysis, respectively [23] . In contrast, the present study showed that late lumen loss increased to 0.60 mm in patients with mild CKD. Although late lumen loss was identical between moderate CKD and dialysis groups, it rose to 0.86 mm for each group. These graded relationships affected the TVR rate at 2 years after PCI. Higher TVR rates in the present study may be related to ''real world'' population characteristics more frequently with diabetic patients and complex lesions. On comparing moderate CKD patients in the TAXUS-IV trial with those in our study, we found that the numbers of diabetic patients were 22.4% and 69%, and those of patients with B2/C complex lesions were 57.9% and 85%, respectively [23] .
A recently published meta-analysis of the results of 6 completed clinical trials, in which a total of 3669 patients were randomly assigned to sirolimus-eluting stent vs. paclitaxel-eluting stent showed significant differences in target lesion revascularization rates (5.1% vs. 7.8%, p < 0.001) favoring the sirolimus-eluting stent [11] . In CKD patients, however, few data directly compared the longterm outcomes of sirolimus-and paclitaxel-eluting stents [24] . Previous studies have reported lower TVR rates ranging from 6.9% to 13% in patients with moderate CKD after sirolimus-eluting stent implantation [9, 25] , whereas moderate CKD patients in the present study showed a TVR rate of 18% after paclitaxel-eluting stent implantation. However, the differences in TVR rates observed between moderate CKD patients with either sirolimus-or paclitaxel-eluting stents were not observed in dialysis patients treated with the 2 types of stents. Most studies have reported higher TVR rates in dialysis patients after treatment with sirolimuseluting stent. TVR or target lesion revascularization rates ranged from 17% to 32.3% [9, 26, 27] , whereas a 2-year TVR rate of 21.4% was observed after treatment with paclitaxeleluting stent. These findings indicate that although the advent of DES has remarkably reduced the incidence of TVR in several high risk subsets, especially in patients on dialysis, there still remains a challenging subset in the era of DES.
The analyses of the present study should be interpreted with caution because of the relatively small population, and the use of data from a single center. Although all patients were scheduled for a follow-up angiogram at 8-12 months after PCI, the rate of follow-up angiography was not equal among the 4 groups. In particular, it was lower for moderate CKD patients, because of the need to avoid the risk of contrast-induced nephropathy. In addition, although continuation of optimal medical therapy, including statins and angiotensin-II receptor blocking agents, has a potential to improve long-term outcomes, we lacked data about the detail of medical treatments during 2 years after PCI, such as discontinuation of medical treatments.
In conclusion, we demonstrated that despite treatment of CAD patients with paclitaxel-eluting stent, cardiac death and TVR rates were significant in moderate CKD and dialysis patients, further suggesting that CKD still has an adverse impact on long-term outcomes of CAD patients treated with DES implant. Therefore, identification of patients with early-stage CKD is crucial. Aggressive medical checkups and treatment of CAD are warranted in the earlier stage of CKD.
